Table 3 RDW distribution as a function of underlying DMARD therapy
DMARD | Intake | n | RDW, mean (SD) | p |
|---|---|---|---|---|
Methotrexate | Yes | 222 | 14,5 (1,44) | < 0,001 |
No | 163 | 14,0 (1,55) | ||
Sulfasalazine | Yes | 9 | 13,7 (1,56) | 0,119 |
No | 376 | 14,3 (1,5) | ||
Hydroxychloroquine | Yes | 30 | 13,9 (1,19) | 0,085 |
No | 355 | 14,4 (1,52) | ||
Leflunomide | Yes | 18 | 14,7 (2,06) | 0,429 |
No | 367 | 14,3 (1,47) | ||
Azathioprine | Yes | 6 | 14,7 (1,23) | 0,273 |
No | 379 | 14,3 (1,51) | ||
bDMARDs | Yes | 139 | 14,2 (1,45) | 0,381 |
No | 246 | 14,4 (1,53) |